Clinical Trial Update: Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update reporting results on the immune response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with ofatumu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2024-12-11